Shots:
- The NMPA has cleared IND application of HLX17 to conduct its clinical study in comparison with Keytruda for treating melanoma, NSCLC, esophageal cancer, HNSCC, CRC, HCC, biliary tract cancer, TNBC, MSI-H/dMMR cancer & gastric cancer
- HLX17 was assessed under pharmacologic comparative trial, preclinical pharmacology study as well as PK/PD & immunogenicity studies that showed similarity b/w the two drugs
- HLX17 (mAb) works by binding with PD-1 receptor to prevent its interaction with PD-L1 & PD-L2, restoring T-cell immune surveillance and enhancing anti-tumor activity
Ref: Shanghai Henlius| Image: Shanghai Henlius| Press Release
Related News:- Accord BioPharma’s Hercessi 420mg (Biosimilar, Herceptin) Receives the US FDA’s Approval to Treat Various HER2-Overexpressing Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
